# Director, CMC – Biologics & ADC at Pathos

- Company: Pathos
- What the company does: Drug development shouldn’t be guesswork, not when patients are waiting. Pathos is building a next-generation biotech with AI at the core. Not as a feature, but as the operating system for how medicines get developed. Backed by NEA.
- Company website: https://pathos.com/
- Type: Startups
- Level: Principal and up
- Location: New York, NY
- Work setup: On-site
- Pay: $210K to $250K base salary per year (USD)
- Posted: 2026-08-10
- Apply by: 2026-10-08
- Apply: https://ats.rippling.com/pathos/jobs/db929ad6-62d3-4e1e-9dc0-681d96212643
- Page: https://www.1752.vc/careers/jobs/pathos-director-cmc-biologics-and-adc/

## About the role

We are seeking a Director, CMC – Biologics & ADC to lead the chemistry, manufacturing, and controls strategy for our antibody and antibody-drug conjugate (ADC) oncology programs. This individual will own upstream and downstream process development, analytical development, and ADC conjugation/manufacturing — from early clinical supply through late-stage development — ensuring phase-appropriate quality, robust and scalable processes, and regulatory-ready documentation.

## What they're looking for

- Define and execute the end-to-end biologics/ADC CMC strategy for one or more oncology programs, spanning antibody drug substance, conjugation, and drug product
- Serve as the CMC program lead and single point of accountability, representing CMC on cross-functional program teams alongside Research, Clinical, Regulatory, and Quality
- Translate program goals and timelines into phase-appropriate development plans, budgets, and risk-mitigation strategies
- Expert in biologics cell line and drug substance development
- Lead upstream process development for antibodies — cell line development oversight, media/feed optimization, and fed-batch/perfusion bioreactor processes from bench through scale-up
- Lead downstream process development — harvest/clarification, Protein A and polishing chromatography, viral clearance, ultrafiltration/diafiltration, and formulation

Tags: Clinical